How To Be A Dynamic Model

Published Sep 17, 2012
Princeton, NJ – Every year, news broadcasts detail reports about communicable diseases in our country. How do disease-control organizations make decisions about how to effectively treat these diseases? Most likely, they analyze the options using dynamic models. “A dynamic model is needed when evaluating an intervention against an infectious disease that 1) has an impact on disease transmission in the target population, or 2) alters the frequency distribution of strains (e.g., genotypes or serotypes),” says Dr. Richard Pitman, PhD, lead author on the paper, “Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5 .” Best practices for designing dynamic transmission modeling studies are presented in this paper. This paper is one of the seven papers in the series on modeling study best practices and is jointly published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and Medical Decision Making, the official journal of the Society for Medical Decision Making (SMDM).

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information: www.ispor.org

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×